Jones Financial Companies’s IGC Pharma IGC Stock Holding History

Jones Financial Companies’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-110	Closed	-$31	–	4827
2025 Q4	$31	Buy	+110	New	+$39	﹤0.01%	4357

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jones Financial Companies's IGC Position: Q1 2026 in Review

Jones Financial Companies sold out of IGC Pharma (IGC) in Q1 2026, closing a stake of 110 shares — an estimated $31 sold.

Jones Financial Companies first reported a position in IGC in Q4 2025 and held it in 1 quarter. The position peaked at $31 in Q4 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

Jones Financial Companies reported no remaining IGC Pharma position as of Q1 2026 after selling out during the quarter.
Jones Financial Companies sold 110 IGC Pharma shares in Q1 2026, an estimated $31.
Jones Financial Companies first reported a position in IGC Pharma in Q4 2025 and held it in 1 quarter.
Jones Financial Companies's IGC Pharma position peaked at $31 in Q4 2025.
35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.